Depression genetics study tracks patients for 5 years to unlock clues
NCT ID NCT07078227
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 415 people with difficult-to-treat depression for 5 years after they joined an earlier genetics study. Researchers will review medical records and registry data to see how patients' depression changes over time, including suicide attempts and treatment responses. The goal is to find patterns and genetic markers that could improve long-term care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict long-term outcomes and personalize treatment for people with hard-to-treat depression.
- What could go wrong
- This is an observational follow-up study, not a treatment trial. It may not lead to immediate changes in care, and results depend on medical record accuracy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 415 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
415 patients from the study "Pharmacogenetics in depressive patients with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6". The study population has been well described in earlier publications.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Participation in the study "Pharmacogenetics in depressive patients with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6" Exclusion Criteria: Not wanting to participate in the follow-up study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anhedonia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Psychiatry Reserach Unit
ACTIVE_NOT_RECRUITINGLund, 221 85, Sweden
-
Research Unit, Office of Psychiatricy, habilitation and technical aid
RECRUITINGLund, 221 85, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can a short, Family-Focused program replace hospital stays for suicidal teens?
- Can a Text-Message program help trauma survivors avoid PTSD and depression?
- Can a website help young people understand depression?
- Can a brain scan and your phone predict where depression goes next?
- Can a tailored therapy ease anxiety and depression in autistic teens?